Live

CRISPR technology

2 articles

DNA Editing Market to Triple to $67.7B by 2030 on CRISPR Boom

GlobeNewswire Inc.

GlobeNewswire Inc.·Apr 7·Bcc Research

DNA Editing Market to Triple to $67.7B by 2030 on CRISPR Boom

Global DNA read, write, edit market projected to surge from $21.4B in 2024 to $67.7B by 2030, driven by CRISPR advances and genomic diagnostics expansion.

ILMNVRTXTMOBEAMPACBgene therapyCAR-T therapies

Vertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams

The Motley Fool

The Motley Fool·Mar 4·Prosper Junior Bakiny

Vertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

VRTXCRSPclinical trialspipeline candidates